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Abstract
Hyper IgE syndrome (HIES) is a multisystem disorder resulting in bone
and immune system abnormalities. It is associated with mutations in STAT3, which
disrupt protein domains responsible for transcriptional function. Patients with HIES
display osteoporosis and enhanced inflammatory cytokine production similar to
hematopoietic Stat3-deficient mice. Since osteoclast and inflammatory cytokine genes
are NFκB targets, these observations indicate a possible deregulation of NFκB
signaling in both mice and humans with STAT3-deficiency. Here, we sought to
examine the role of STAT3 in the regulation of NFκB-mediated gene expression
through analysis of three HIES STAT3 point mutations in both hematopoietic and nonhematopoietic cells. We found that IL-6-induced tyrosine phosphorylation of STAT3
was partially or completely abrogated by HIES mutations in the transactivation domain
(V713L) or SH2 domain (V637M), respectively, in both hematopoietic and nonhematopoietic cells. By contrast, IL-6-induced tyrosine phosphorylation of an HIES
mutant in the STAT3 DNA-binding domain (R382W) was intact. The R382W and
V713L mutants significantly reduced IL-6-dependent STAT3 transcriptional activity in
reporter gene assays. Moreover, the R382W and V637M mutants significantly
diminished IL-6-responsive expression of the endogenous STAT3 target gene, Socs3,
as assessed by quantitative real-time PCR (qPCR) in the RAW macrophage cell line.
These observations indicate the HIES mutants dominantly suppress the transcriptional
activity of wild type STAT3, albeit to varying degrees. All three HIES mutants
enhanced LPS-induced expression of the NFκB target genes IL6 (IL-6), Cxcl10 (IP10), and Tnf (TNFα) in RAW cells, as indicated by qPCR. Furthermore, overexpression
of wild type STAT3 in Stat3-deficient murine embryonic fibroblasts significantly
reduced LPS-stimulated expression of IL6, Cxcl10, and IL12p35. In addition, in a
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primary murine osteoclast differentiation assay, a STAT3-specific SH2 domain inhibitor
led to significantly increased levels of osteoclast-specific gene expression. These
results suggest that STAT3 serves as a negative regulator of NFκB-mediated gene
expression, and furthermore imply that STAT3 mutations associated with HIES
contribute to the osteopenia and inflammation observed in HIES patients.	
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Introduction

Hematopoiesis:
The cellular components of the immune system are generated through the
process of hematopoiesis or blood formation. This begins with the differentiation of
pluripotent hematopoietic stem cells (HSCs) in the bone marrow to a multipotent
progenitor (MPP) and eventually to the development of the various effector subsets of
both innate and adaptive immunity (Figure 1a) [1]. The cells of the adaptive immune
response, namely T- and B- lymphocytes, differentiate from the common lymphoid
progenitor (CLP), whereas the generation of innate immune cells occurs primarily
through a process known as myelopoiesis, beginning with the common myeloid
progenitor (CMP). These cells include the granulocytes (neutrophils, basophils, and
eosinophils), dendritic cells, and macrophages. They act to protect the body from
infection through secretion of various inflammatory cytokines along with physically
interacting with the pathogens to remove them from the system. Macrophages are a
prime example of this. However, given the right cytokine milieu, macrophages can also
continue to differentiate further into cells known as osteoclasts in a process termed
osteoclastogenesis.

Osteoclastogenesis:
The bone microenvironment is a highly dynamic system under the control of two
main cell types: bone-producing osteoblasts and bone-resorbing osteoclasts. In
normal individuals, there exists a unique balance between the functions of these two
cell types to maintain a consistent bone density. However in individuals where one of
these cell types is either over- or under-reactive, the pathologies of osteopetrosis
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Figure 1a. Schematic representation of hematopoiesis, the
process by which the cells of innate and adaptive immunity are
formed.
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(bone hardening) or osteoporosis (reduced bone density) arise. The
osteoclastogenesis pathway, beginning with the hematopoietic stem cells through the
monocyte/macrophage lineage and eventually terminating in the production of boneresorbing osteoclasts, is under the control of multiple cytokine as well as transcription
factor signals (Fig. 1b). The Receptor-activator of NFkB (RANK) pathway is essential
for osteoclastogenesis and disruption of this pathway leads to severe osteopetrosis
[2][3][4]. In vitro, osteoclasts are generated from bone marrow macrophages after
addition of the soluble ligand for RANK, RANK ligand (RANKL), for 3-5 days and
develop generally from fusion of multiple macrophages to form the multinucleated
osteoclasts, which posses the ability to resorb bone [5][6].
RANK has been identified as a member of the tumor necrosis factor receptor
(TNFR) super family [7]. In a ligand-dependent manner [8], after binding of RANKL,
the receptor trimerizes, inducing recruitment of members of the TNFR-associated
factor (TRAF) family, primarily TRAF6 although TRAFs 1, 2, 3, and 5 have been
shown to bind RANK in vitro [9]. TRAF6 is an E3-ubiquitin ligase, and functions as
such in concert with an E2-ubiquitin conjugating complex of Ubc13 and Uev1A [10].
Uev1A, an E1-ubiquitin ligase, activates the ubiquitin monomers and then
subsequently transfers them transiently to Ubc13, an E1/E2-ubiquitin conjugating
enzyme. Ubc13 then transfers the activated ubiquitin to TRAF6, which ligates it to its
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Figure 1b. Schematic representation of osteoclastogenesis, the
process by which cells of the monocyte/macrophage lineage
differentiate to form the bone resorbing osteoclasts which are
necessary for bone development and homeostasis.
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target proteins [11]. Upon RANK activation, the TRAF6/Ubc13/Uev1A complex is
recruited to a specific motif, on the cytoplasmic tail of RANK, which it binds with high
affinity [12]. Through auto-ubiquitination of TRAF6 on a lysine residue at position 63,
known as K63-linked polyubiquitination, Tak1-binding protein 2 (TAB2) can bind
TRAF6. TAB2 then acts as a scaffold to allow binding of the TGFβ-activating kinase 1
(TAK1)/Tak1-binding protein 1 (TAB1) complex [13]. This association of TAK1/TAB1
with TRAF6 allows TRAF6 to ubiquitinate TAK1, thus activating it [14]. This complex
goes on to activate both the MAPK and the NFkB signaling pathways via
phosphorylation cascades resulting in activation of AP-1 and Nuclear Factor-kappa B
(NFκB), respectively (Figure 2).
Activation of the RANK signaling pathways in osteoclast precursors eventually
leads to the terminal differentiation of multinucleated osteoclasts capable of resorbing
bone matrix. These osteoclasts have multiple phenotypic markers that serve as
identifiers of the stage of osteoclast differentiation. As the osteoclast precursors begin
to fuse, they up-regulate Tartrate-resistant acid phosphatase (TRAP) and Calcitonin
receptor (CALC) on the cell surface [15]. Cathepsin K (CSK), a cysteine protease, is
also up-regulated at this point and primarily functions in the resorptive process [16].

NFκB-mediated inflammation:
While the TRAP, CALC and CSK osteoclast-specific markers have not been
determined to be direct targets of NFκB, it is clear that NFκB is an important modulator
of osteoclast differentiation [17][18]. NFκB also functions in the innate immune
system. One of its main roles is in production of pro-inflammatory mediators
[19][20][21] via pathways that have been activated by pathogens recognized via a sect
of innate immune receptors knowns as Toll-like receptors (TLRs), including TLR4
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Figure 2. Schematic representation of RANKL signaling. After
RANKL binding its cognate receptor, TRAF6 becomes
ubiquitinated, activating it and allowing it to activate downstream
signaling resulting in MAPK and NFκB activation. This activation
leads to the transcription of osteoclast specific genes and the
differentiation of macrophages into bone-resorbing osteoclasts.
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[22][23][24]. This inflammatory response is especially important for macrophages, as
they are a primary effector of the innate immune system and one of the first defenses
against infection [25].
Inflammatory signaling in macrophages occurs through various receptors both
on the cell surface and in the cytosol. Macrophages highly express a variety of TLR,
which recognize conserved pathogen-associated molecular patterns (PAMPs). These
PAMPs are conserved motifs commonly found on different types of pathogens,
including bacteria, fungi, and viruses. For example, TLR2 recognizes peptidoglycan,
TLR7 recognizes single-stranded RNA, and TLR4 recognizes lipopolysaccharide
(LPS) [22]. The effector products of each of the TLRs vary. Activation of TLR4, for
example, induces activation of the NFkB and MAPK signaling cascades resulting in
the production of a variety of inflammatory gene products [23][24][26].
Binding of LPS to TLR4 results in the dimerization of the receptors, and binding
of the intracellular adaptor proteins TIR-domain-containing adapter-inducing interferonβ (TRIF) or myeloid differentiation primary response gene (MyD88) [27]. This elicits the
binding and activation of IL1-receptor associated kinases 1, 2, and 4 (IRAK1/2/4)
[28][29]. These adaptor molecules then recruit the E3-ubiquitin ligase TRAF6, similar
to the RANK pathway. Polyubiquitinated TRAF6 then activates the NFkB and MAPK
pathways as discussed previously, leading to expression of inflammatory cytokines
including but not limited to tumor necrosis factor alpha (TNFα), Interleukin-6 (IL-6), IL12, Interferon-gamma induced protein 10 (IP-10; Cxcl10), and IL1-β (Figure 3)
[30][31][32][33]. Interestingly, LPS has also been shown to induce osteoclastogenesis
from bone marrow precursors as one might expect from the similarity of the TLR4 and
RANK signaling pathways [34][35].
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Figure 3. Schematic representation of LPS-induced TLR4
signaling. After LPS binds, the receptor dimerizes and recruits
the scaffold protein MyD88 resulting in the activation of IRAK and
TRAF6. TRAF6 then activates downstream signaling events
leading to NFκB and MAPK activation and the transcription of
inflammatory genes such as IL-6, IP-10, IL-12, and TNFα.
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Another pathway highly important in myeloid cell development, function and
inflammation is the JAK-STAT pathway [36-38]. Binding of a cytokine ligand to its
cognate trans-membrane receptor primarily activates this pathway. The signaltransducer and activator of transcription (STAT) proteins have been shown to be
important for myeloid cell development, homeostasis and function including
inflammatory gene expression as discussed below [39-43].

The JAK/STAT pathway:
The STAT family of proteins consists of 7 members: STAT1, 2, 3, 5a, 5b, and 6
[44]. STATs can form homo- or hetero-dimers in the cytoplasm upon specific
stimulation of growth factor or cytokine receptors on the cell surface. Once activated,
the STATs function as transcription factors to regulate cell growth, differentiation,
survival, and function [45]. Figure 4 depicts a more detailed look at how the cytokines
transduce a STAT-dependent signal to the nucleus to stimulate gene transcription.
After binding of the cytokine or growth factor ligand to the receptor, the monomers
dimerize bringing the receptor-associated kinases on the cytoplasmic tails together
[46][47]. This allows cross-phosphorylation of the kinases as well as the receptor
cytoplasmic tails at specific tyrosine residues [47]. These phosphorylated residues
create docking sites for the STAT proteins to bind via their Src-Homology 2 (SH2)
domains [48]. The receptor-associated kinases then phosphorylate the STAT proteins
on a specific tyrosine residue (Y705 for STAT3), allowing the STAT monomers to
associate into dimers via SH2-phosphotyrosine-interactions [49][44]. These activated
STAT dimers now translocate to the nucleus where they can function as transcription
factors. This pathway has been termed the canonical pathway of STAT signaling [50].
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Figure 4. Schematic representation of canonical STAT3
signaling. IL-6 binds IL-6Rα, either soluble or membrane bound
depending on the cell type. This complex binds the
transmembrane signaling component, gp130. Dimerization of
this receptor leads to cross-phosphorylation allowing the binding
of JAK1/2. These kinases further tyrosine phosphorylate the
receptor allowing STAT3 monomers to bind via their SH2
domain. JAK then phosphorylate STAT3 on tyrosine 705 allowing
dimerization, nuclear translocation and transcription of STAT3
target genes like SOCS3.
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As was stated earlier, STATs function broadly in immune cell function,
differentiation, and maintenance. The physiological role of each STAT family member
has been widely studied through the use of both complete and conditional knockout
mice [51]. While each is important in its own right, STAT3 has been the only STAT to
show early embryonic lethality [52] which indicates its importance for cell growth,
differentiation, and function early in the developmental process [53].

STAT3:
STAT3 has a structure like other STAT proteins (Figure 5). It contains an Nterminal region, followed by a coiled-coiled domain, and a DNA-binding domain
[54][53] The C-terminal region contains the SH2-domain and finally a transactivation
domain (TAD) [53]. The important tyrosine residue is located in the SH2 domain
adjacent to the TAD. A serine residue that also undergoes phosphorylation most likely
via serine/threonine kinases is located in the TAD at position 727. Phosphorylation at
this serine residue has been shown to enhance STAT3 mediated transcription [55] but
is unnecessary for STAT3 DNA binding [56].
Signaling via STAT3 can occur similarly to other STAT proteins, via the
canonical pathway (Figure 4). In the IL-6 response, STAT3 activation involves both the
IL-6-receptor alpha chain (IL-6Rα), which binds IL-6, followed by the binding of IL-6/IL6Rα to the signaling subunit, gp130 [57]. Additional cytokines that activate STAT3 via
gp130 include: IL-10, IL-11, IL-21, IL-23, Leukemia Inhibitory Factor (LIF), and
Oncostatin M (OSM). Granulocyte-colony stimulation factor (G-CSF) and Interferonalpha/beta (IFN-α/β) also activate STAT3 although not through gp130-mediated
signaling [58][59][60].
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Figure 5. Schematic structure of the WT STAT3 protein
representing the different protein domains as well as significant
amino acid residues within these domains.
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Recently, two groups identified two non-canonical STAT pathways. In
Drosophila melanogaster, it has been shown that the single STAT protein, STAT92E,
while unphosphorylated, can mediate heterochromatin structure and stability via its
association with heterochromatin protein 1 (HP-1) [61]. Subsequently, it was shown
that STAT3, phosphorylated solely on the serine residue at position 727, could
regulate cellular respiration in mitochondria via interactions with electron transport
chain complexes I and II [62] and this function comes at the expense of its canonical
transcriptional function. These discoveries are in stark contrast to the traditional view
of STATs as transcription factors. While the Drosophila STAT protein is more closely
related to STAT5, it has yet to be shown whether any of the other STATs have a
similar function in Drosophila or in mammals.
It would seem however that the canonical view of STAT3 might not be the only
function this particular protein has in the cell. In support of this idea, unphosphorylated
STAT3 has a transcriptional function as well and upregulates a number of oncogenes
found in various types of cancer [63]. A function for STAT4 and STAT6 was also
identified in regulating chromatin activation status through regulation of epigenetic
activation and repression marks [64]. STAT4 was shown to increase the histone 3
lysine 4 trimethylation (H3K4me3), known to be an activating marker; STAT6 on the
other hand decreased the amount of H3K27me3, a known repression marker. Another
member of the JAK/STAT pathway, namely JAK2, has also recently been identified to
have a role in regulating heterochromatin structure through inhibiting the binding of
heterochromatin protein 1-α (HP1-α) by phosphorylating tyrosine 41 (T41) on histone
H3 (H3) leading to a more open and active chromatin conformation [65].
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STAT3 and inflammation:
Due to the inability to generate genome-wide STAT3 knockout mice because of
the embryonic lethality [52], it is necessary to study STAT3’s function in a lineagespecific context. Hematopoietic STAT3-deficient mice have been produced [43]. These
mice display mild to moderate osteoporosis [66] as well as a Crohn’s disease-like
phenotype characterized by increased infiltration of myeloid cells most likely
responsible for the observed increase in production of inflammatory cytokines and
severe deterioration of the bowel and intestinal tract [43][67].
STAT3 is important for both positively and negatively regulating inflammation.
This is evidenced not only through its known activation by IL-6 [57], an inflammatory
cytokine, but also through the dependence of inflammatory IL-17-producing helper T
cells (TH17) on STAT3’s regulation of retinoic acid receptor-related orphan receptor-γT (RORγT), a TH17-lineage specific transcription factor [68]. STAT3’s antiinflammatory role has also been well characterized. Evidence suggests this occurs
primarily through IL-10, a known anti-inflammatory cytokine, whose expression is
dependent on STAT3 in both mice and humans [69][70]. IL-10 also signals through
STAT3 to inhibit the proliferation of macrophages [71]. STAT3 auto-regulates
inflammatory cytokine signaling via induction of suppressor of cytokine signaling 3
(SOCS3), which competes with STAT3 for binding to the cytoplasmic portion of the
receptor thus attenuating signaling [72]. Inflammation has not only been shown to be
important in the immune system setting, but through epidemiological studies, it is
evident that inflammation is a key player in oncogenesis [73][74].
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STAT3 and cancer:
The link between inflammation and cancer development is an intense area of
study because of the implication that targeting the immune system may lead to more
effective cancer treatment and prevention [60][75]. As was noted earlier, STAT3 is an
important regulator of inflammation and cellular growth control, and thus has been a
focus for its role in promoting tumorigenesis. STAT3 signaling is commonly overactive
in solid tumors [76][77]. The relationship between the tumor cells and tumorassociated non-transformed cells is important for cancer progression and cell survival
possibly due to a STAT3 feed-forward loop [59]. STAT3 along with NFκB are important
mediators of cancer-associated inflammation [73] and persistent activation of STAT3
in immune cells leads to defective immune responses against the tumor [60].
These two molecules are important not only for the growth and survival of
tumors, but also function to stimulate the epithelial-mesenchymal transition of tumors,
which is the first step in their metastasis to other organs [78-80]. The effectors of this
transition can be inflammatory cytokines such as IL-6, IL-1, TNFα, and transforming
growth factor-β (TGFβ) [78] leading to expression of NFκB and STAT3 targets
important for this transition [79][80].
STAT3 seems to have a dual role in inflammation and cancer. In non-immune
cells, STAT3 functions to promote cell survival and proliferation [81]. In tumorassociated immune cells, unphosphorylated STAT3 interacts with NFκB to produce
inflammatory signals that aid the cancer cells in survival and eventual metastasis
[82][83]. Moreover, in myeloid cells, STAT3 regulates cell survival, growth and function
[36][42], but also is responsible for anti-inflammatory responses via inducing IL-10
expression and participating in IL-10 signaling, including suppression of TLR4-induced
inflammatory gene expression [38][69][70][71].
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The immunosuppressive functions of STAT3 signaling via IL-10 have been well
characterized, as has its function in promoting oncogenesis through its proinflammatory interactions with NFκB. Recently, STAT3 has been implicated as the
effector of another human syndrome whose phenotype encompasses each of the
known functions for STAT3 both in inflammation and cancer.

Hyper-IgE Syndrome:
Hyper-Immunoglobin E (IgE) syndrome (HIES), otherwise known as “Job’s
Syndrome” due to the skin lesions reminiscent of the lesions of Job in the Bible’s Old
Testament, is a primary immunodeficiency with both an autosomal dominant (AD) or
autosomal recessive (AR) heritability pattern. The characteristic phenotype of this
disease includes elevated levels of IgE in the serum, skin lesions, cold abscesses,
recurrent staphylococcal infections of the skin and respiratory tract, as well as bone
abnormalities affecting the spine, teeth, and long bones, specifically osteopenia (Table
1, & [84]). Several types of cancer have also been correlated with this disease
[85][86][87]. Until recently, the genetic cause for this disease was unknown.
In 2007, two groups concordantly discovered the genetic basis for this disease.
Multiple individual mutations in the STAT3 gene were identified in individuals
presenting with the AD form of HIES ([88][89]. The authors noted that the mutations
occurred primarily in the DNA-binding domain, SH2-domain, and the TAD, and most
likely affected the protein structure such that the mutant STAT3 proteins acted like
dominant negatives by interfering with the wild-type STAT3 and preventing its
activation or its ability to bind DNA. Since then, a fair amount of research has been
focused on determining how STAT3 induces the phenotypic abnormalities associated
with HIES.
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Table 1. Phenotype of STAT3 deficient mice and
humans with HIES

	
  

23	
  

`

Possibly the most devastating pathology of this disease is the recurrent

infections in the majority of patients. These can range from infections caused by the
Staphylococcus and Streptococcus families [90] to the Pseudomonas and Aspergillus
families. In most cases, these infections have been deemed the cause of death [91].
Therefore, most research to date has been focused on how the loss of STAT3 impairs
the immune system in such a way as to allow these microbes to proliferate unchecked.
Several groups have made key observations in this respect.
Patients with HIES have an observed lack of Th17 cells both in vitro and in vivo
[92][93][94]. Given STAT3’s importance for the expression of retinoid–related orphan
receptor γT (RORγT) [68], the loss of Th17 cells, which depends on RORγT for their
development, makes sense. This severe lack of Th17 could play a large part in the
susceptibility to fungal and bacterial pathogens found often in patients with HIES.
Further evidence suggests that STAT3’s function in IL-10 signaling may also be
important for the imbalanced inflammatory response in patients with HIES. While
lymphocyte numbers in the blood remain normal, dendritic cells (DC) were found to be
unable to become tolerogenic in the presence of IL-10, as well as to induce naïve
CD4+ T cells to becoming inducible T-regulatory cells (iTregs) [95]. DC from HIES
patients were also shown to secrete more inflammatory cytokines, even in the
presence of IL-10 [96].
By comparing what is known about patients with HIES and mice with
hematopoietic specific deletion of Stat3, it is reasonable to propose that STAT3 is
important for regulating bone development, immunity against bacterial and fungal
pathogens, and production of NFκB-regulated inflammatory cytokines. However, no
direct evidence to date suggests how STAT3 is affecting bone development and
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homeostasis, or how STAT3 is affecting NFκB-mediated inflammatory gene
expression in these two models.

Project Goal:
Traditionally, STAT3 has been considered to solely act as a transcription factor
in the regulation of pathways leading to cell growth, survival, and differentiation as well
as in regulation of inflammation. Although STAT3 has been shown to be important in
bone development [66], little data exists elucidating the exact mechanism as to how it
is involved. Data from our lab and others (H. Zhang, unpublished data)[82][97]
indicates a role for STAT3 in regulating NFkB signaling in the hematopoietic system.
The goal of this project was to examine how the point mutations identified in HIES
affect STAT3’s function in NFkB-mediated gene expression and by doing so, gain a
more detailed understanding of the role for each domain in this regulation.

Methods
Cell Lines, Culture Conditions and Cytokine/LPS Treaments:
Primary murine macrophages were generated from total bone marrow, collected from
6-8 week old C57BL/6 mice, by culturing in DMEM containing 20% fetal calf serum
(FCS) and 20% conditioned medium from L929 cell supernatants (source of M-CSF)
for 3 days. Primary murine osteoclasts were then generated by addition of 50ng/mL
RANKL (R&D Systems, #390-TN-010) for 4 days. RAW cells (mouse macrophage cell
line) were cultured in DMEM supplemented with 10% FCS. Similarly, the STAT3-null
murine embryonic fibroblast cell line (L1) was maintained in DMEM with 10% FCS.
The RAW and L1 cells expressing WT STAT3 or one of the STAT3 point mutations
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were generated by retroviral transduction. Briefly, 3x105 cells were plated in a 6-well
plate and allowed to adhere for 30 minutes at 37° C. 1 mL of retrovirus was then
added to 0.5 mL complete media along with 8ug/mL polybrene. Cells were spun at
2300 rpm for 1 hour, then allowed to incubate for 4 hours before media was aspirated
and replaced with DMEM plus 10% FCS. Cells were subject to sorting for GFP+ cells
after 48 hours. For assays involving analysis of STAT3 transcriptional activity, cells
were treated with murine IL-6 (25ng/mL: R&D systems #406-ML-005) or mIL-6 plus
mouse soluble IL-6 receptor alpha (sIL-6Rα) (25ng/mL: R&D systems #1830-SR-025)
for 30 minutes (immunoblots), 3 hours (luciferase assays), or indicated time points
(quantitative real-time PCR).For primary osteoclast differentiation assay and STAT3
inhibitor quality control, cells were stimulated with 20 ng/mL recombinant human GCSF. For inflammatory gene expression analysis, 1x106 RAW cells were plated in a 12
well plate in 1mL media and starved overnight in DMEM with 1% FCS. RAW cells
were then stimulated with Lipopolysaccharide (LPS) (100ng/mL: Sigma #L3024) for
the indicated time points. 5x105 L1 cells were plated in a 6 well dish and starved
overnight in DMEM with 1% FCS. L1 cells were then stimulated with LPS (100 ng/mL)
for indicated time points. All cells were maintained in a humidified incubator at 37° C
and 5% CO2.
STAT3 mutant generation:
STAT3 cDNAs encoding individual point mutations (R382W, V637M, and V713L) were
generated by Dr. Huiyuan Zhang using the QuikChange II Site-Directed Mutagenesis
kit (Stratagene, #200523) as described in the manufacturers protocol. The presence of
the mutations was confirmed by DNA sequencing. The truncated STAT3 mutants were
generated (TAD: X. Xie and Watowich unpublished results, Δ133: L. Zhang [100])
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using a PCR-based strategy and confirmed by gel electrophoresis and DNA
sequencing.
Production of VSVg-pseudotyped MCSV-based STAT3 retroviruses:
cDNAs encoding WT STAT3 or the three HIES point mutants described previously
were cloned into the pMX-IRES-GFP retroviral vectors via digestion with Sph1 and
Not1 and confirmed by gel electrophoresis. Retroviruses were then generated using
the 293T packaging cell line via the calcium-phosphate transfection method. Briefly,
14ug plasmid cDNA along with cDNA encoding the packaging constructs (8ug VSVg,
10ug Gag/Pol) were mixed with CaCl2 and water. Hepes-buffered saline (HBS) was
then added drop by drop to the DNA/CaCl2 mixture while bubbling. This mix was then
allowed to sit for 5 minutes before adding drop-wise to the plate of 293T cells (60-80%
confluency) in DMEM with 10% FCS and 20uM chloroquine. Cells were incubated for
8 hours and then medium was replaced with fresh DMEM plus 10% FCS. Supernatant
containing viral particles was collected after 48 and 72 hours and used fresh or frozen
(stored at -80°C).
STAT3 SH2 domain inhibitor:
A STAT3-specific SH2 domain inhibitor (73g) was kindly provided by Dr. John
McMurray (M.D. Anderson Cancer Center). The unreconstituted inhibitor was stored at
-20° C. For working concentrations, inhibitor was reconstituted in 99.9% pure DMSO at
and aliquots were frozen at -80° C. For STAT3 inhibition experiments, the inhibitor was
added at the indicated concentrations and replaced every 12 hours for the indicated
time period.
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Preparation of whole cell lysates, SDS-polyacrylamide gel electrophoresis, and
immunoblot analysis:
Cells were treated as indicated (section: Cell Lines, Culture Conditions and
Cytokine/LPS Treaments) and then washed with 1X PBS. Laemmli gel sample buffer
(2% SDS, 80mM Tris pH 6.8, 15% Glycerol, 0 v.01% Bromophenol Blue, 1%
Betamercaptoethanol) was added and the cell pellet was sonicated and boiled (10
minutes, 100°C) for whole cell lysates. 5x105 (Raw)/2.5x105 (L1) cell equivalents were
separated on 10-15% SDS-polyacrylamide gels by electrophoresis. Protein was then
electrophoretically transferred to a nitrocellulose membrane for antibody staining.
Membranes were briefly washed in ddH20 and then blocked for 1 hour at room
temperature. For phosphorylated STAT3, 5% BSA in TBST (1X TBS, 0.05% Tween20) was used for blocking. For total STAT3 and RAN, 5% milk in PBST (1X PBS,
0.05% Tween-20) was used. For total and phosphorylated JNK, 5% milk in TBST was
used for blocking. For Tubulin, 1% BSA in TBST was used for blocking. Membranes
were then incubated overnight at 4° C with primary antibodies in their respective
diluents: Phosphorylated STAT3 (1:1000 in 5% BSA-TBST, Cell Signaling #9131S ),
STAT3 (C-20/H-190, 1:1000 in 5% milk-PBST, Santa Cruz Biotechnologies, #SC-482
& SC-7179), Phosphorylated JNK (1:500 in 5% BSA-TBST), total JNK1 (1:500 in 5%
milk in PBST), Tubulin (1:1000 in 1% BSA-TBST, Sigma #T9026), Ran (1:1000 in 5%
milk-PBST, Santa Cruz Biotechnology, #SC-1156). After overnight incubation,
membranes were washed with PBST three times followed by addition of secondary
antibody for incubation at room temperature for 2 hours (pSTAT3/STAT3/pJNK, antirabbit IgG-HRP, GE-life sciences #NA934; Tubulin/JNK1, anti-mouse IgG-HRP, GElife sciences #NA9310; and for Ran, anti-goat IgG-HRP, Santa Cruz #SC-2020, were
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used). Membranes were washed 3 more times in PBST followed by development
using West Pico Substrate (Thermo Scientific, #34087).
Quantitative Real-time polymerase chain reaction (qPCR):
Cells were treated as indicated and then lysed in Trizol Reagent (Molecular Research
Center, #TR118). Total RNA was extracted per the manufacturer’s protocol and RNA
concentration was analyzed on a Nanodrop-1000. 1ug of total RNA was subjected to
reverse transcriptase PCR (RT-PCR) using the IScript system (Biorad, #1708891).
cDNA was diluted 1:5 and 5uL was used for each sample in qPCR. Samples were
combined in a 20uL mixture containing nuclease-free water, specific oligonucleotides,
and iQ SYBR Green mastermix (Biorad, #1708882). Each sample was run in duplicate
on a Biorad C1000 Thermal Cycler CFX96 Real-time system. PCR conditions were:
95°C 3 min, (95°C 10 seconds, 59°C 20 seconds, 72°C 30 seconds) X 39 cycles.
Samples calculations were relative to an internal control, 18s rRNA. Data were
analyzed using the ΔΔCt method in Microsoft Xcel using the formula [Relative
expression level=power(1.8, (Control Ct value – Target Ct value))*107]. P values were
calculated using either Student’s t-test or 2-way ANOVA with a Bonferroni post-test.
Oligonucleotide sequences for qPCR:
Please see Table 2
Transient Transfection for STAT3 overexpression:
293T cells were grown to 60-80% confluency prior to transfection. 10ug of DNA was
transiently transfected using the calcium phosphate method described in section:
Production of VSVg-pseudotyped MCSV-based STAT3 retroviruses. Cells were
incubated with DNA precipitate and 20uM chloroquine in DMEM plus 10% FCS for 6
hours and then the media was replaced. Cells were then incubated for 48 hours before
analysis by immunoprecipitation and immunoblotting.
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Flag-immunoprecipitation and immunoblotting:
10-20x106 cells were pelleted and washed with 1X PBS containing a protease inhibitor
cocktail (Roche, #11873580001) and placed on ice. Pellets were lysed in 0.5mL nondenaturing isotonic triton lysis buffer (1% Triton X-100, 50mM Tris-Cl ph 7.4, 300mM
NaCl, 5mM EDTA, 0.02% Sodium Azide) containing the protease inhibitor cocktail
(Roche) on ice for 5 minutes. Lysates were spun at 14,000 RPM at 4° C for 15
minutes. Supernatants were collected and 20uL Protein-G agarose beads (Santa Cruz
Biotechnology, #SC-2002) was added to pre-clear lysate of non-specifically bound
proteins. Samples were rotated at 4° C for 1 hour. Samples were then spin to remove
cell debris and supernatants were collected. Protein concentration was detected and
normalized between samples. One-tenth of the total volume was removed to use for
the input controls. 2uL of anti-Flag M2 antibody (Sigma, #F3165) were then added and
samples were rotated overnight at 4° C. Then Protein-G agarose beads (40uL) were
added and samples continued to rotate at 4° C for 1 hour. Samples were spun and
supernatants were discarded. Beads were washed 3X with isotonic Triton lysis buffer
containing protease inhibitor and 1X with PBS containing protease inhibitor and then
resuspended in 40uL Lammeli sample buffer and boiled for 10 minutes. 40uL
immunoprecipitated and input samples were run on a 15% polyacrylamide gel and
electrophoretically separated and STAT3 expression was analyzed by immunoblot.
Transfection of STAT3-deficient mouse embryonic fibroblasts for Luciferase assay
1x104 STAT3-/- MEFs were plated in duplicate per well of a 48 well plate in 0.2 mL
complete DMEM the night before transfection. On the following day, cells were
transfected using Lipofectamine LTX and PLUS reagent (Invitrogen #15338030)
according to the manufacturers protocol. Briefly, 0.4ug of total DNA was diluted in 40
uL serum free media per well. PLUS reagent (0.4uL) was added to the diluted DNA
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and incubated at room temperature for 15 minutes. Lipofectamine LTX was added
(0.2uL) to DNA:PLUS mixture, and incubated for 30 minutes at room temperature.
Finally, 40 uL/sample was added to each well of the 48-well plate and incubated for
40-48 hours. The ratio of DNA to lipid was optimized according to the manufacturers
optimization protocol.
Luciferase assays
Transfected STAT3-deficient mouse embryonic fibroblasts were assayed for luciferase
activity using the Promega Dual-luciferase reporter kit following an amended
manufacturers protocol. After a 3 hour stimulation with 25ng/mL IL-6 and 25ng/mL sIL6Rα, cells in a 48-well plate were lysed with passive lysis buffer for 15 minutes at room
temperature. 5 uL lysate per sample was mixed with 5uL luciferase assay reagent II
and then the firefly luciferase was read using a Sirius Luminometer from Burthold
Detection systems. Stop and Glo reagent was added (5uL) and the background renilla
luciferase activity was detected. Each sample was transfected in duplicate, and then
averaged before being normalized to the average renilla luciferase reading.

Results:
Generation of the STAT3 mutant constructs
STAT3 contains 5 distinct protein domains: N-terminal region, coiled-coiled
domain, DNA-binding domain, SH2-domain and C-terminal transactivation domain
(TAD). Traditionally the DNA-binding region, SH2 domain, and TAD are considered to
be important for STAT3’s function as a transcription factor, whereas the others may be
involved in protein-protein interactions [53].
To evaluate how STAT3 functions in osteoclastogenesis and inflammatory gene
expression, we first generated STAT3 constructs containing mutations in each of these
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domains (Fig. 6). Previous members of our lab generated an N-terminal truncated form
of STAT3, termed Δ133 for the loss of the first 133 amino acid residues [100], as well
as a construct that lacks the entire transactivation domain at the C-terminus [X. Xie
and S. Watowich, unpublished results]. These were generated via a polymerase chain
reaction (PCR)-based strategy. A published construct, EE/VVV, was provided by Drs.
Curt Horvath and Jim Darnell, and has been shown to elicit dominant negative activity
[54]. Finally, we chose three of the published point mutations identified in patients with
HIES (R382W, V637M, and V713L) and generated them via site-directed mutagenesis
[H. Zhang and S. Watowich, unpublished results]. R382W is located within the DNAbinding domain and is predicted to function similarly to the EE/VVV mutant by allowing
STAT3 phosphorylation and dimerization but preventing its binding to promoter
elements on the DNA. V637M is located within the SH2-domain, and published reports
show that it lacks the ability to become tyrosine phosphorylated after EGF stimulation
of transiently transfected COS-7 cells [98]. V713L is found in the transactivation
domain but adjacent to the SH2 domain in tertiary protein structures as seen through
virtual protein modeling [E. Ohashi and S. Watowich, unpublished results]. While there
are no reports on how this mutation affects STAT3 signaling, we hypothesize that it will
act similarly to the V637M mutation due to its proximity to the SH2 domain and the
important tyrosine residue at position 705.
To confirm that these constructs were expressed in vitro, we transiently
transfected 293T cells with plasmids encoding each mutant, all containing in-frame Cterminal FLAG epitope tags, and evaluated their expression by immunoprecipitation
with anti-FLAG antibodies and immunoblotting for total STAT3. We found that each
construct was expressed at relatively similar levels, excluding the EE/VVV and TAD
mutants (Fig. 7). Each mutant construct was expressed from a green fluorescent
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Figure 6. Schematic representation of the various STAT3
mutants we and others generated to analyze the function of the
different domains and point mutants in HIES. Red circles denote
the specific amino acids mutated in each construct.
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Figure 7. Transient overexpression of the STAT3 mutants in
293T cells. Total cell lysates were immunoprecipitated with antiFLAG antibodies and then immunoblotted for total STAT3. A
portion of lysate before immunoprecipitation (Input) was
examined for total STAT3 expression and RAN as a loading
control.
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protein (GFP)-containing vector to assist us in tracking the expression of mutant
proteins throughout our experiments. Prior to each experiment, the GFP expression
was checked via fluorescent microscopy and multiple times throughout the project a
confirmatory immunoblot was run to verify continued expression of the mutants. Based
on this result, we chose to focus on comparing wild-type (WT) STAT3 with the three
HIES point mutations in our studies.

Effects of HIES mutants upon phosphorylation of endogenous STAT3
The STAT3 mutations identified in patients with HIES have been assumed to be
dominant negative due in part to the heterozygosity of HIES patients as well as in vitro
assays performed with mutated STAT3 isoforms in cell culture systems [88]. The
dominant negative action of mutated STAT3 in HIES is proposed to lead to the severe
clinical defects with this syndrome including osteopenia, increased incidence of
infection, and high IgE serum levels. However, of the three mutations we were
interested in, only the mutation located in the DNA-binding domain (R382W) has been
assayed for dominant negative activity via luciferase assays [88][89]. We wanted to
determine whether the other mutations, V637M and V713L, also elicited dominant
negative inhibition of STAT3 function.
We initially utilized retroviral transduction to express each mutant in a murine
macrophage cell line (RAW cells). To confirm the expression of the mutants in our
system, we performed immunoprecipitation and immunoblotting assays with FLAG and
STAT3 antibodies, respectively. We found that each mutant was expressed at equal
amounts (Fig. 8).
To determine if the mutants affect activation of endogenous STAT3, we
stimulated RAW cells expressing each mutant with soluble IL-6 (sIL-6) for 30 minutes
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Figure 8. Stable overexpression of WT STAT3 and STAT3 HIES
mutants in murine macrophage cell line, RAW. Total cell lysates
were immunoprecipitated with anti-FLAG antibodies then
immunoblotted for total STAT3. A portion of lysate before
immunoprecipitation (Input) was examined for total STAT3
expression and RAN as a loading control.
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and then examined STAT3 tyrosine phosphorylation by immunoblotting. We found
total STAT3 tyrosine phosphorylation amounts were similar or slightly higher in cells
expressing the R382W mutant (mutated in the DNA-binding domain), compared to
cells with WT STAT3 overexpression (Fig. 9a). By contrast, overexpression of the
V637M mutation significantly diminished the level of STAT3 tyrosine phosphorylation
compared to WT STAT3. The level of this tyrosine phosphorylation was similar to the
level of tyrosine phosphorylation observed in uninfected RAW cells stimulated with sIL6 (Fig. 9b). Importantly, cells expressing the V713L mutation, which is located in the
TAD but adjacent to the SH2 domain, showed a slightly increased amount of total
STAT3 tyrosine phosphorylation compared to uninfected macrophages, while
exhibiting significantly less compared to cells overexpressing WT STAT3 (Fig. 9a).
Together these data suggest that the mutations in the SH2 domain and TAD affect
STAT3 tyrosine phosphorylation, whereas mutations in the DNA-binding domain do
not.

Activation of STAT3 HIES mutants
Due to our data examining total STAT3 tyrosine phosphorylation when
overexpressing the HIES mutants, we intended to identify whether the mutants alone
could become activated via IL-6 stimulation. Previous studies have shown that in
transiently transfected COS-7 cells, epidermal growth factor (EGF) stimulation induced
STAT3 tyrosine phosphorylation in cells transiently transfected with both WT STAT3
and the R382W mutant STAT3, but not in cells expressing the V637M mutant [98]. We
sought to confirm this observation within cells stably expressing the STAT3 HIES
mutants in the absence of endogenous or overexpressed WT STAT3, under IL-6
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Figure 9. IL-6 induced STAT3 tyrosine phosphorylation in RAW
cells expressing the STAT3 HIES mutants. (a) Western blot of
total cell lysates of RAW cells overexpressing the different
STAT3 HIES mutants stimulated with or without 25 ng/mL sIL-6
for 30 minutes. Total STAT3 and RAN immunoblots are included
as loading controls. (b) Western blot of uninfected RAW cells
unstimulated or stimulated with 25 ng/mL sIL-6 for 30 minutes to
examine the level of endogenous STAT3 phosphorylation.
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stimulation conditions, as well as shedding light on the activation ability of the V713L
mutant, which has not been tested to date.
Using STAT3-deficient MEFs, we stably reconstituted each STAT3 HIES
mutant. To confirm that the mutants were expressed, and that the parental cells were
truly STAT3-deficient, we examined total STAT3 protein expression by
immunoblotting. Uninfected cells and cells infected with a GFP-containing empty
vector (referred to as GFP-empty vector henceforth) were used as negative controls,
while 293T cells were used as a positive control (Fig. 10). We found that the HIES
mutants showed similar expression levels. The uninfected and GFP-empty infected
cells confirmed a lack of STAT3 expression in STAT3-deficient MEFs. By contrast, the
TAD, Δ133, and EE/VVV mutants were expressed at significantly lower amounts
versus the HIES point mutants.
To examine directly the phosphorylation potential of the STAT3 HIES mutants,
we used a combination of sIL-6 and soluble IL-6 receptor-α (sIL-6Rα; STAT3-deficient
MEFs do not express IL-6Rα) to stimulate reconstituted STAT3-deficient MEFs for 30
minutes and then assayed for STAT3 tyrosine phosphorylation by immunoblotting (Fig.
11). Consistent with our data from the RAW cells, we found increased tyrosine
phosphorylation in cells expressing the R382W mutant compared to cells expressing
WT STAT3. We also confirmed previous reports showing the complete lack of tyrosine
phosphorylation of the V637M mutant [98]. Interestingly, we found that the V713L
mutant was phosphorylated following IL-6 stimulation; however, this appeared to occur
less efficiently than the WT and R382W mutants when total STAT3 level was taken
into account. Together these data indicate that the mutation in the DNA-binding
domain does not inhibit tyrosine phosphorylation of STAT3 but rather enhances it (Fig.
9 & 11). The SH2-domain mutation completely abrogates phosphorylation of this
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Figure 10. Stable overexpression of WT STAT3 and STAT3
mutants in a STAT3-deficient MEF cell line. Whole cell lysates
were immunoblotted for total STAT3 and RAN as a loading
control. 293T cell whole cell lysate was used as a positive
control. Non-infected and GPF-empty vector infected cells were
used as negative controls.
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Figure 11. IL-6 induced STAT3 tyrosine phosphorylation in
STAT3-deficient MEFs expressing the STAT3 HIES mutants. The
STAT3-deficient MEF cell line stably expressing the STAT3 HIES
mutations were unstimulated or stimulated with 25 ng/mL sIL-6
and 25 ng/mL sIL-6Rα for 30 minutes and then whole cell lysates
were examined by western blot of tyrosine phosphorylated
STAT3 and total STAT3 expression. Ran was used as a loading
control.
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mutant, and the TAD mutation allows STAT3 to be phosphorylated albeit at a much
lower level compared to WT.

Transcriptional activity of STAT3 HIES mutants
Next, we sought to identify whether the STAT3 HIES mutants were able to
exhibit transcriptional activity. The suppressors of cytokine signaling (SOCS) proteins
are competitive inhibitors of JAK/STAT signaling, which act via competition for binding
to the tyrosine residues of gp130 [99]. The Socs3 promoter has been shown to contain
a STAT3 binding site [100][101] and it is induced by STAT3 activation whereby
SOCS3 potently inhibits further STAT3 activation after cytokine stimulation [101][102].
To analyze the transcriptional activity of the HIES mutants after IL-6 stimulation,
we treated STAT3-deficient MEFs, reconstituted with the mutants, with sIL-6 and sIL6Rα. We then analyzed Socs3 mRNA expression at different time points by qPCR.
Socs3 mRNA expression peaked at 30 minutes of IL-6/sIL-6Rα treatment (Fig. 12a)
and was induced up to 40 fold (Fig. 12b) in WT cells. Figure 12a depicts the
expression level of Socs3 RNA relative to an internal control gene. Figure 12b depicts
the fold change of Socs3 RNA relative to the unstimulated control. In contrast, IL-6responsive Socs3 expression was significantly reduced in cells expressing the HIES
mutants (p<0.001) compared to WT STAT3, with cells expressing the R382W and
V637M mutants displaying no Socs3 induction compared to unstimulated samples
(p<0.001). The V713L mutant elicited expression of Socs3, which was increased by 10
fold in comparison to the R382W and V637M mutants (p<.001). However, this
induction was still much diminished in comparison to Socs3 expression in WT STAT3
cells. The Socs3 expression kinetics with the V713L mutant mirrored the expression
pattern of Socs3 in WT STAT3 cells, with peak expression at 60 minutes post	
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Figure 12. IL-6 induced Socs3 expression in STAT3-deficient
MEFs expressing the STAT3 HIES mutants. The MEFs were
unstimulated or stimulated with 25 ng/mL sIL-6 and 25 ng/mL
sIL-6Rα for 30, 60, or 120 minutes and then total RNA was
extracted, converted to cDNA, and Socs3 mRNA expression was
analyzed by qPCR. (a) Relative expression shown as arbitrary
units normalized to the relative expression of 18s rRNA. (b) Fold
change relative to the non-stimulated (NS) sample for each
mutant. Data are mean +/- s.e.m, *p<0.05, **p<0.01, **p<0.001.
Analyzed using a 2-way ANOVA followed by a Bonferroni posttest.
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stimulation. These data indicate that the DNA-binding and SH2-domain mutations
completely abolished STAT3’s transcriptional ability, whereas the V713L mutation did
not. However, the level of transcriptional activity of the V713L mutant was significantly
lower level than the WT cells. This correlates well with the partially decreased
phosphorylation of the V713L mutant seen in both RAW and STAT3-deficient MEFs
(Figs. 9 and 11).

Dominant negative effects of STAT3 HIES mutants
While it is clear that each HIES mutation we tested severely diminishes the
intrinsic transcriptional ability of the mutants of STAT3 (Fig. 12), it remained to be
determined whether these mutations interfere with the transcriptional function of WT
STAT3 thereby exhibiting proposed dominant negative activity. It has been shown that
the R382W mutant does decrease STAT3 gene reporter activity in transiently
transfected HepG2 cells after IL-6 stimulation [88]. Therefore we intended to confirm
the dominant negative activity of this mutation and examine the activity of the V637M
and V713L mutations as well.
Using STAT3-deficient MEFs, we transiently expressed WT STAT3 with a GFPempty vector or vectors encoding the HIES mutants, in different WT:mutant ratios,
along with a STAT3 reporter plasmid containing 3 consecutive STAT3 consensus
binding sites upstream of the firefly luciferase gene. After 48 hours, we stimulated the
cells with IL-6 and sIL-6Rα and then assayed 3 hours later for luciferase activity using
the Dual-luciferase reporter assay system, to measure STAT3 transcriptional activity
(Fig. 13). WT STAT3 alone stimulated a 2-3 fold increase in STAT3 reporter activity in
response to IL-6/sIL-6Rα, relative to the empty vector non-stimulated samples. The
R382W mutant significantly reduced STAT3 reporter activity by 2-fold at a 4:1 ratio to
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Figure 13. The dominant negative activity of STAT3 containing
the HIES mutations. The STAT3-deficient MEF cell line was
transiently transfected with a STAT3 consensus reporter, an
GFP-empty vector or WT STAT3 and each HIES mutant in
varying ratios to WT. Cells were stimulated with 25 ng/mL sIL-6
and 25 ng/mL sIL-6Rα for 3 hours and firefly luciferase activity
was quantified. Data represent mean +/- s.e.m., *p<0.05,
**p<0.01, ***p<0.001 using a 2-way ANOVA and Bonferroni posttest. Firefly values were normalized to a renilla luciferase control,
values displayed are normalized to the non-stimulated empty
vector sample.
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WT (p<.05), and approximately 3 fold at a 10:1 ratio (p<0.01). The V713L mutation,
also showed a trend toward dominant negative activity at a 4:1 ratio to WT, and
significantly reduced STAT3 reporter activity at a 10:1 ratio with WT (p<0.001).
Surprisingly, the mutation located in the SH2 domain, which led to a complete lack of
phosphorylation and lack of transcriptional activity, failed to significantly diminish
STAT3 reporter activity, although there was a decrease of reporter activity at a 10:1
ratio with WT (Fig. 13).
To further examine the dominant negative activity of these mutants in a less
artificial setting, we examined the relative level of Socs3 mRNA after IL-6 stimulation in
RAW cells stably expressing each of the HIES mutants. We stimulated these cells for
30, 60, or 120 minutes and then assayed Socs3 mRNA expression by qPCR (Fig. 14).
Socs3 expression peaked at 30 minutes in cells overexpressing WT STAT3, and
stayed elevated even at 2 hours post-stimulation. When each HIES mutant was stably
overexpressed, the Socs3 mRNA expression had similar expression kinetics, peaking
at 30 minutes post-stimulation. However, Socs3 expression was significantly
decreased in comparison to WT STAT3 (p<.001) at 60 minutes for the R382W and
V637M mutants. The V713L mutant, on the other hand, never resulted in significantly
lower Socs3 expression compared to WT STAT3. Additionally at 2 hours, the R382W
mutant maintained significantly decreased Socs3 mRNA expression (p<.05) whereas
the V637M mutant did not, although Socs3 expression was still low compared to WT.
Together, these data suggest that the DNA-binding domain, SH2 domain, and TAD
mutations impart a dominant negative ability upon STAT3, although differences appear
to exist in their effects depending on the assay system used.
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Figure 14. Socs3 expression after sIL-6 stimulation in
macrophages expressing the STAT3 HIES mutants. The RAW
cells stably expressing the STAT3 HIES mutations were
unstimulated or stimulated with 25 ng/mL sIL-6 for 30, 60, or 120
minutes and total RNA was extracted and converted to cDNA.
cDNA was then analyzed for SOCS3 expression by qPCR. Data
are mean +/- s.e.m, *p<0.5, ***p<0.001 using a 2-way ANOVA
and Bonferroni post-test. Values are represented as arbitrary
units relative to 18s rRNA.
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Effect of STAT3 function on osteoclast-specific gene expression
In addition to determining whether specific HIES mutations were inhibiting
STAT3’s function via interfering with its phosphorylation or transcriptional ability, we
sought to further examine how these mutations affected the function of STAT3 in
phenotypes observed in both hematopoietic STAT3-deficient mice and patients with
HIES.
Upon exposure to RANKL, cells of the monocyte/macrophage lineage begin to
differentiate into osteoclasts [103]. RANKL stimulation results in the activation of NFκB
[104], and osteoclast differentiation is NFκB dependent [17]. As these cells further
differentiate from the precursors to mature activated osteoclasts, they up-regulate
expression of genes specific for their function, which include, but are not limited to
Acp5/ACP5 (TRAP), Ctsk/CTSK (CSK), and Calcr/CALCR (CALC) (Fig 1b)[15][16].
We originally sought to investigate whether and how STAT3 regulates
osteoclast differentiation using RAW cells, which have been shown to undergo
RANKL-responsive osteoclast differentiation [105-108], however we had difficulties
inducing sufficient differentiation of these cells. Therefore, we obtained a small
molecule STAT3 inhibitor from Dr. John McMurray at M. D. Anderson Cancer Center.
This inhibitor functions as an antagonist for the SH2-domain of STAT3. By physically
interacting with this domain, the inhibitor should not only prevent STAT3’s interaction
with the phospho-tyrosine on the cytoplasmic domain of the STAT3-activating receptor
thereby inhibiting its tyrosine phosphorylation, but also prevent dimerization and
subsequent activation, very much similar to how we hypothesize the V637M mutation
affects STAT3. To verify the effect of the inhibitor on STAT3 tyrosine phosphorylation,
we isolated total bone marrow from C57BL/6J mice and stimulated cells with
granulocyte-colony stimulating factor (G-CSF), a STAT3-activating cytokine, in the
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presence of increasing concentrations of the STAT3 inhibitor. Since the inhibitor was
dissolved in dimethylsulfoxide (DMSO), we used DMSO treatment for 30 minutes as a
control. We examined cell lysates by immunoblotting for tyrosine phosphorylated
STAT3, total STAT3, and α-tubulin, with that latter serving as a loading control (Fig.
15a). These assays showed that as the concentration of the inhibitor increased, the
amount of STAT3 tyrosine phosphorylation substantially decreased and eventually
was undetectable. As expected, the inhibitor had no effect on the relative abundance
of STAT3 protein, as the amount of total STAT3 remained the same.
Next, we cultured total murine bone marrow from C57BL/6J mice in the
presence of conditioned medium containing macrophage-colony stimulating factor (MCSF) for 3 days to generate bone marrow-derived macrophages. The macrophages
were subsequently cultured for 4 days in the presence of RANKL with varying
concentrations of the STAT3 inhibitor. The gene expression of the three osteoclastspecific genes was analyzed by quantitative real-time PCR (qPCR)(Fig. 16). We found
that with increasing concentrations of inhibitor, and thus less activated STAT3, the
expression of Acp5 (TRAP), Ctsk (CSK), Calcr (CALC) were all significantly upregulated. This indicates a role for the STAT3 SH2-domain, as well as activated
STAT3, in the negative regulation of osteoclast differentiation and expression of genes
important for osteoclast function.

Analysis of the effect of the HIES mutations on inflammatory gene expression in
mouse macrophages stimulated with LPS
NFκB activity is not only important for osteoclastogenesis, but is also highly
involved in the inflammatory response [19][20][21]. To determine whether STAT3 is
involved in another NFκB-mediated pathway, and whether the HIES point mutations
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Figure 15. STAT3 and STAT5 G-CSF induced phosphorylation in
the presence of a STAT3 inhibitor. Total murine bone marrow
were isolated from C57BL/6J mice and stimulated with 20 ng/mL
granulocyte colony stimulating factor (G-CSF) +/- an antagonistic
inhibitor for the STAT3 SH2 domain at 50, 500, or 5000 ng/mL.
Whole cell lysates were analyzed by western blot examining (a)
p-STAT3, total STAT3, (b) p-STAT5 and total STAT5 expression.
α-tubulin was used as a loading control.
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Figure 16. RANKL-induced osteoclast specific gene expression
in the presence of a STAT3 inhibitor. BMDM were stimulated with
50 ng/mL RANKL for 4 days in the presence of increasing
concentrations of the STAT3 SH2 domain inhibitor. Total RNA
was isolated, converted to cDNA, and expression of Apc5 (Trap),
Ctsk (CSK), and Calcr (Calc) were analyzed by qPCR. Data are
mean +/- s.e.m., *p<0.05, **p<0.01, ***p<0.001 analyzed using a
student’s T-test. Data are represented as arbitrary units relative
to 18s rRNA.
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Figure$16.$RANKL$induced$osteoclast)speciﬁc$gene$
expression$of$murine$bone)marrow$derived$
macrophages$in$the$presence$of$a$STAT3$inhibitor$

deregulate this pathway, we examined LPS-responsive gene expression. LPS is a
known ligand for TLR4. Activation of TLR4 by LPS also induces the activation of NFκB
[23][24][26]. Thus, we overexpressed the HIES mutant constructs in the mouse
macrophage cell line, RAW, and examined LPS-responsive gene expression.
After confirmation of the expression of the STAT3 HIES mutants in RAW cells
(Fig. 8), we stimulated the cells with LPS 0, 1, 2 or 6 hours and assayed the
expression of inflammatory genes known as NFκB targets, including Il6, Tnf (TNFα),
and Cxcl10 (IP-10) (Fig. 17). We found in cells overexpressing WT STAT3 that Il6
expression peaked at 6 hours post-stimulation with an approximate 200-fold induction
relative to unstimulated cells. Cxcl10 mRNA also peaked with similar kinetics with an
approximate 15-fold increase in expression relative to unstimulated cells. Tnf mRNA
expression appeared much earlier, at 1 hour, and remained at similar levels
throughout the time-course. In addition, Tnf mRNA had the lowest fold induction of the
three genes (2x increase) compared to unstimulated cells. RAW cells overexpressing
the STAT3 V637M mutant showed significantly higher expression of Il6 at 6 hours both
in relative expression (p<.001) and fold induction (p<.01) (Fig. 17, upper left and right
panels, respectively), compared to cells expressing WT STAT3. This Il6 expression
reached as high as a 400-fold increase relative to unstimulated cells, almost twice
what WT STAT3 was found to induce. The V637M mutant displayed similar kinetics of
IL6 expression to WT STAT3. Cells expressing this mutant displayed comparable
mRNA expression levels and kinetics for Cxcl10 and Tnf, although the kinetics of Tnf
expression were slightly different with the expression peaking at 2 hours versus WT
which peaked at 1 hour. Cells expressing the V713L mutant displayed significantly
higher IL-6 expression, similar to the V637M mutation, again reaching almost twice the
induction of WT. However, statistical significance was not obtained with either Cxcl10
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Figure 17. LPS-induced inflammatory gene expression in RAW
cells overexpressing the STAT3 HIES mutants. RAW cells
expressing the various STAT3 HIES mutants were unstimulated
or stimulated with 100 ng/mL LPS for 1, 2 or 6 hours and then
total RNA was extracted. cDNA was prepared and analyzed for
expression of IL6, Cxcl10 (IP-10), and Tnf by qPCR. Data are
mean +/- s.e.m., *p<0.05, **p<0.01, ***p<0.001 analyzed by a 2way ANOVA and a Bonferroni post-test. Data is represented as
arbitrary units relative to 18s rRNA and fold change normalized
to unstimulated cells for each mutant.
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or Tnf mRNA expression. Interestingly, while overexpressing STAT3 with the R382W
mutation resulted in slightly higher levels of all three genes, in no case was this
significant. Thus the HIES mutations we investigated lead to enhanced NFκBmediated inflammatory gene expression in macrophages following TLR4 activation,
which suggests that STAT3 function may be important for restraining this gene
expression.

Analysis of the LPS-induced inflammatory gene expression in mouse embryonic
fibroblasts overexpressing STAT3
While it is evident that STAT3 negatively regulates NFκB-mediated
inflammatory gene expression in macrophages, and that the domains thought to be
important for transcriptional function participate in this regulation, we were interested in
whether STAT3 also participates in a similar manner in non-hematopoietic tissues.
This would establish STAT3 as a more global regulator of inflammatory gene
expression. To evaluate this possibility, we used a STAT3-deficient MEF cell line and
reconstituted with WT STAT3 or GFP-empty vector (Fig. 10) as a reference for gene
expression in the absence of STAT3 and to control for the effect the infection may
have had on this gene expression.
To examine the effect of STAT3 on NFκB-mediated inflammatory gene
expression in fibroblasts, we stimulated the MEFs expressing either WT STAT3 or
GFP-empty vector with LPS and then assayed expression of NFκB inflammatory gene
targets via qPCR (Fig. 18). We found a markedly decreased expression of Il6, Cxcl10,
and Il12 mRNA after WT STAT3 overexpression compared to the GFP-empty
transduced STAT3-deficient cells. The relative expression levels of Il6 and Cxcl10
became significantly less in WT cells than GFP-empty at 2 hours (p<.05) (Fig. 18a),
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Figure 18. LPS-induced inflammatory gene expression in STAT3deficient MEFs overexpressing WT STAT3. STAT3-deficient
MEFs stably expressing either a GFP-empty vector or WT
STAT3 were unstimulated or stimulated with 100 ng/mL LPS for
2, or 4 hours and then total RNA was extracted. The mRNA was
reverse transcribed to cDNA which was then analyzed for IL6,
Cxcl10 (IP-10), and IL12 by qPCR. (a) Data are represented as
arbitrary units relative to 18s rRNA. (b) Data are represented as
fold change relative to the unstimulated sample. Data are mean
+/- s.e.m., *p<0.05, **p<0.01, ***p<0.001 analyzed by 2-way
ANOVA and Bonferroni post-test.
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and a similar result was obtained when examining the fold change (Fig. 18b). Il6,
Cxcl10 and Il12 were also significantly induced in GFP-empty transduced cells
compared cells expressing WT STAT3 (Fig. 18b). When WT STAT3 was absent, Il6
and Cxcl10 expression were induced 2 fold more than when STAT3 was present. Il12
was induced up to 7 fold when similarly compared.
Interestingly, the forced expression of STAT3 also changed the kinetics of the
expression for both IL6 and IL12. IL6 mRNA expression peaked at 2 hours in cells
expressing GFP-empty vector whereas the WT STAT3 overexpressing cells exhibited
delayed induction peaking at 4 hours (Fig. 18a). Significantly, IL12 showed no
induction when STAT3 was present and was 7 fold less than empty-vector transduced
STAT3-deficient cells (Fig. 18b). Thus, in non-hematopoietic tissues, STAT3 functions
similarly as in immune cells by inhibiting LPS-induced NFkB-mediated inflammatory
gene expression.

The effect of HIES mutants on LPS-induced inflammatory gene expression in
STAT3-deficient MEFs
Our results showed that overexpression of STAT3 HIES mutants resulted in
increased inflammatory gene expression in macrophages (Fig. 17), and that STAT3
overexpression in STAT3-deficient MEFs dampened inflammatory gene expression
(Figs. 18a & 18b), indicating STAT3 negatively regulates inflammatory gene
expression in both systems. Thus, we sought to examine the affect of these mutants
on inflammatory gene expression in STAT3-deficient MEFs. We stimulated MEFs that
stably express the HIES mutants with LPS for 2 or 4 hours and assayed for Il6,
Cxcl10, and Il12 mRNA expression by qPCR. Surprisingly, we found no increase in
either Il6 or Cxcl10 expression at either time point (Fig. 19). We did observe increased
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Figure 19. LPS-induced inflammatory gene expression in STAT3deficient MEFs expressing the STAT3 HIES mutants. STAT3deficient MEFs stably expressing WT STAT3 or the STAT3 HIES
mutants were unstimulated or stimulated with 100 ng/mL LPS for
2 or 4 hours and then total RNA was extracted. cDNA was
generated and analyzed for expression of IL6, Cxcl10 (IP-10),
and IL12 by qPCR. Data are represented as arbitrary units
relative to 18s rRNA. Data are mean +/- s.e.m., *p<0.05,
**p<0.01, analyzed by a 2-way ANOVA and Bonferroni post-test.
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Il12 gene expression levels in cells expressing the HIES mutants compared to cells
expressing WT STAT3, however they were determined to be statistically insignificant.
Il6 showed significantly lower expression in cells with the V637M and V713L mutants
in comparison to cells with WT STAT3. Cxcl10 showed significantly lower expression
only in the V713L mutant cells. Thus, expressing the HIES mutants in MEFs lacking
endogenous STAT3 does not enhance their expression of LPS-induced inflammatory
gene compared to WT STAT3 as was initially hypothesized.

Examination of mitogen activated protein kinase (MAPK) signaling after LPS
stimulation in macrophages expressing the HIES mutants
Both the cytokine profile we observed with the HIES STAT3 point mutations in
murine macrophages (Fig. 17), and the cytokines found in the blood of patients with
HIES [84][89], indicate a possible role for involvement of both NFκB and MAPK
signaling in hematopoietic cells. Il6 and Cxcl10 are regulated by both NFκB and AP-1
binding in their promoters [109][110] and Tnf expression has also been linked to both
NFκB and AP-1 activation [111]. In addition, in B-cells, NFκB regulates AP-1 activation
after LPS stimulation [112]. Therefore, we hypothesized that the enhanced
inflammatory gene expression in RAW cells could be due to the activation of both
signaling pathways.
Using the RAW cells overexpressing either WT STAT3 or STAT3 HIES
mutants, we stimulated them with LPS for 5, 15, or 30 minutes and then analyzed
phosphorylation of c-Jun N-terminal Kinase 1 (JNK1) by immunoblot (Fig. 20). JNK1 is
downstream of TAK1 but upstream of AP-1 in the MAPK pathway [113][114]. JNK1
becomes activated after tyrosine phosphorylation [114]. In cells overexpressing WT
STAT3, we found that JNK was activated by 30 minutes post-stimulation. Conversely,
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Figure 20. LPS-induced JNK1 activation in RAW cells expressing
the STAT3 HIES mutants. The RAW cells stably expressing the
STAT3 HIES mutants were unstimulated or stimulated with 100
ng/mL LPS for 5, 15, or 30 minutes and then whole cell lysates
were isolated and analyzed by western blot for tyrosine
phosphorylated JNK1 and total JNK1 expression. RAN was used
as a loading control.
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when any of the HIES mutants were overexpressed, pJNK1 levels appeared as early
as 5 minutes with significantly higher expression, compared to macrophages
expressing WT STAT3, as stimulation time increased to 15 and 30 minutes.
Our preliminary data examining whether the STAT3 HIES mutants affect NFκB
activation, using analysis of phosphorylated-IκBα and degradation of IκBα, indicates a
possible enhancement of NFκB activation as well but further confirmation is required
(data not shown). Thus, our results suggest that loss of STAT3 function leads to
enhanced MAPK signaling, which may be partially responsible for the increased
inflammatory gene expression we observe in the macrophages expressing the HIES
STAT3 mutants. Our preliminary results also indicate a possible increase in NFκB
signaling in the presence of STAT3 HIES mutant overexpression.
Discussion
STAT3 is an important molecule in many diverse and distinct cellular processes
including survival, proliferation, differentiation, inflammation and oncogenesis
[36][41][43][67}[76][77]. Traditionally STAT3 has been described as a transcription
factor, similar to the other STAT family members [45]. New evidence suggests that this
may be an oversimplified view of the ways STAT3 functions within a cell [61][62][63].
Previous studies have described an anti-inflammatory role for STAT3 through
participation in and regulation of IL-10 signaling [69][70]. In this project, we examine
another mechanism whereby STAT3 may negatively regulate inflammation and
differentiation, via crosstalk with the NFκB signaling pathway. We sought to better
understand how this regulation occurs, and to gain more insight into how the mutations
in HIES lead to enhanced inflammatory gene expression.
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Previous studies have identified various mutations in the STAT3 gene in
humans diagnosed with Hyper-IgE syndrome [88][89]. The majority of these are point
mutations with several deletions also identified. Interestingly, all of these mutations
were found in domains thought to be important for STAT3 transcriptional activity
[53][54]. To examine how the different domains affect STAT3’s regulation of NFκBmediated gene expression, we chose to analyze three of these point mutations, one in
each different domain (DNA-binding, SH2, TAD) (Fig. 6).
To understand the mechanism by which these mutants were affecting the
function of STAT3, we first had to analyze their activation potential. Previous studies
have suggested that STAT3 containing a mutation in the DNA-binding domain
(R382W) can be tyrosine phosphorylated whereas STAT3 containing a mutation found
in the SH2 domain (V637M) cannot be [98]. These studies were conducted in COS-7
cells, which express a low level of endogenous STAT3 [55], transiently transfected
with either STAT3 mutant construct after EGF stimulation, therefore we wanted to
confirm this observation in cells stably expressing the HIES mutants without any
confounding endogenous STAT3.
Using STAT3-deficient MEFs expressing the STAT3 HIES mutants, we
confirmed the previous observation that the R382W mutant can be tyrosine
phosphorylated [98] (Fig. 11). We also observed slightly higher amounts of tyrosine
phosphorylation of the R382W mutant than that in WT STAT3 expressing cells despite
similar total STAT3 levels (Fig. 11). We also observed this enhanced tyrosine
phosphorylation when we examined total STAT3 activation in RAW cells expressing
the STAT3 HIES mutants (Fig. 9a). This may indicate a mechanism that fails to
attenuate the cytokine signal leading to prolonged phosphorylation. One explanation
could be the lack of SOCS3 (Fig. 14) due to the loss of the R382W mutant’s
	
  

77	
  

transcriptional activity (Fig. 12). SOCS3 has been shown to be an important inhibitor of
cytokine signaling, especially after IL-6 stimulation in vivo [72]. We also confirmed the
previous observation that the V637M mutation completely prevents STAT3 from
becoming tyrosine phosphorylated [98]. We hypothesize the mutation may somehow
prevent STAT3 binding the phosphotyrosine on gp130, similarly to how the STAT3
inhibitor leads to diminished STAT3 tyrosine phosphorylation after G-CSF stimulation
(Fig. 15a). However, further analysis is required to confirm that this mutation physically
prevents STAT3’s association with the phosphotyrosine on gp130 or by some other
unknown mechanism. Since the identification of the mutation in the TAD (V713L) has
been established [98], no research has been focused on determining how this
mutation alters STAT3 function to result in the HIES phenotype. To our knowledge we
are the first to show that the V713L mutation does not completely block STAT3’s ability
to become tyrosine phosphorylated (Fig. 11). However, STAT3 containing this
mutation becomes phosphorylated less efficiently than either WT STAT3 or STAT3
with the R382W mutation. Interestingly, and in accordance with this modest
phosphorylation, we also showed this mutant has a low level of transcriptional ability
(Fig. 12), which would make it difficult to ascribe dominant negative ability to this
mutant, at least in terms of severely blocking WT STAT3’s transcriptional function.
In order for a protein to be considered dominant negative, it must interfere with
the function of the WT protein often exhibiting a phenotype more severe than the loss
of only a single allele [115]. To determine whether each of the STAT3 HIES mutants
was dominant negative, we overexpressed these mutants in a murine macrophage cell
line (RAW), which expresses endogenous STAT3 (Fig. 9b). We sought to examine
whether these mutants affected total STAT3 phosphorylation in the presence of
endogenous STAT3. We again observed an enhanced tyrosine phosphorylation with
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the R382W mutant and moderately less tyrosine phosphorylated STAT3 in the V713L
expressing cells (Fig. 9a). The data from the STAT3-deficient MEFs after IL-6
stimulation indicates the V637M mutant has a complete defect in tyrosine
phosphorylation (Fig. 11). Therefore, we conclude that the phosphorylated STAT3
observed in the RAW cells expressing the V637M STAT3 mutant (Fig. 9a) is solely the
endogenous STAT3. Additionally, this phosphorylation level is similar to the level
found in uninfected RAW cells (Fig. 9b). Unfortunately, due to the intrinsic tyrosine
phosphorylation of the R382W and V713L mutants, it was difficult to conclude whether
they abrogated phosphorylation of endogenous STAT3. We may be able to infer their
effect, however, based on what we know about the location of each mutation. The
R382W mutation is located in the DNA-binding domain and has no effect on the
intrinsic tyrosine phosphorylation of STAT3; therefore we could hypothesize that this
mutant would have no inhibitory effect on phosphorylation of endogenous STAT3. The
V637M mutation is in the SH2 domain and therefore completely prevents tyrosine
phosphorylation of STAT3, presumably due to a defect in the interaction at the
receptor. This also should not affect endogenous STAT3 phosphorylation because the
phosphorylation occurs with the monomeric STAT3. For the same reason, we can
hypothesize the V713L mutant would not affect endogenous STAT3 phosphorylation.
So the question remained, if these mutations are not affecting the phosphorylation of
WT STAT3, do they truly exert dominant negative activity and if so, how is this
accomplished?
The initial paper describing the STAT3 mutations within the DNA-binding
domain in patients with HIES tested the dominant negative activity of the R382W
mutant through analysis of its effect on the ability of WT STAT3 to initiate transcription
of a STAT3 reporter [88]. In this study, Minegishi et al analyzed the dominant negative
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activity in cells expressing a low level of endogenous STAT3 [116] and did not report
the ratio of WT STAT3 to mutant STAT3 required for inhibition. Therefore, we sought
not only to confirm the dominant negative activity of the R382W mutant and determine
the potency by which it accomplishes this activity, but also examine the dominant
negative activity of the V637M and V713L mutants. We chose to use the STAT3deficient MEF cell line to eliminate the confounding effect of endogenous STAT3 and
more accurately determine the amount of mutant protein needed to inhibit WT STAT3
activity. As expected, we found that the R382W STAT3 mutant inhibited WT STAT3’s
ability to initiate transcription of a STAT3 luciferase reporter; however this inhibition
required four times as much mutant protein to obtain statistical significance (Fig. 13).
The V637M mutant, which failed to be phosphorylated and most likely failed to
inhibit phosphorylation of endogenous STAT3, also failed to inhibit WT STAT3’s
transcriptional function as judged by the reporter assay. In contrast, macrophages
stably expressing this mutant exhibited significantly reduced Socs3 gene expression
(Fig. 14). This is indicative of the V637M mutant protein interfering with endogenous
WT STAT3 function [101][102]. The disagreement between these two sets of data
could be a technical issue given the amount of mutant needed to elicit any inhibition in
the luciferase assays (4:1 at the least), or it could indicate that the reduction in Socs3
gene expression is a due to a mechanism independent of directly blocking
transcription. Interestingly, the V713L mutation exhibits a trend toward dominant
negative activity over WT STAT3’s transcriptional function (Fig. 13) as low as a 4:1 WT
to mutant ratio with significance arising at 1:10. However, while the level of Socs3 is
diminished compared to WT, the change is insignificant and nowhere near the level
observed with the R382W and V637M mutants (Fig. 14). This may be due in part to
the inherent transcriptional ability of this mutant on its own (Fig. 12).
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The only mutation for which any direct mechanism has been elucidated is the
R382W mutation, which was shown to completely abrogate the DNA-binding ability of
STAT3 to the Socs3 promoter [117]. Our Socs3 gene expression results in both
macrophages and MEFs, and our reporter assay results with this mutation, correlate
well with this data. On the other hand, no evidence has been provided regarding the
mechanism by which the other two mutants, V637M and V713L, functionally inhibit
STAT3 activity. Our data confirm the total lack of phosphorylation of the V637M mutant
[98] but show that it most likely does not affect endogenous WT STAT3
phosphorylation or direct transcriptional function. However this mutant still interferes
with WT STAT3’s function as shown through the reduced Socs3 expression in RAW
cells expressing this mutant. Initially, we hypothesized that in the HIES patient setting,
the reduction in WT STAT3 activity in the presence of the V637M mutant allele could
be due to an overall reduction in available WT STAT3 within the cell. This is due to the
fact that ideally at a 1:1 WT to mutant ratio, the presence of this mutant would reduce
the amount of transcriptionally active WT STAT3 by 50%. Due to the importance of
STAT3 in many cellular processes [36][42][43][52] and the conclusion that this
mutation is responsible for the HIES phenotype in several individuals [89], this
hypothesis seems plausible. However, given that mice lacking one full WT STAT3
allele show no adverse affects and do not present with an HIES phenotype [52], this
may not be the explanation. However it is possible this mutation does block the ability
of WT STAT3 to initiate transcription but due to technical difficulties or the sensitivity of
our luciferase assay we were unable to detect it. To confirm this hypothesis would
require further study.
As we showed, the V713L mutation doesn’t fully inhibit phosphorylation of
STAT3, thus it has a minimal amount of transcriptional activity. Even so, it significantly
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reduced WT STAT3’s ability to transcribe the luciferase gene in our reporter assays
and marginally reduced SOCS3 expression in RAW cells. We believe this lends
evidence to our hypothesis that this mutation, by participating in the formation of the
SH2 domain, may lead to unstable interactions either at the receptor or once
dimerized. This could lead to attenuated dimerization once phosphorylated or once
bound to promoters. Further elucidation of this mechanism would require either coimmunoprecipitations with the receptor or in vitro binding assays. It is also possible
that this mutation changes the conformation of the TAD such that it is no longer able to
enhance transcription [55].
Now that we have a little better idea of how these mutants function, we sought
to utilize them to determine how STAT3 may be interacting with the NFκB signaling
pathway resulting in the phenotypes observed in patients with HIES and mice lacking
hematopoietic STAT3 (Table 1). We chose to focus primarily on the increased
osteoporosis and inflammation. The cytokine profile we examined was based on
previous reports regarding known NFκB and AP-1 targets, namely Il6, Cxcl10 (IP-10),
Tnf (TNFα), and Il12 [78][109][110][111][118][119]. As figures 1 and 2 depict, the
RANKL and LPS pathways share several common elements upstream of the most
striking similarity, NFκB activation. Both pathways use TRAF6 at early stages to lead
to the activation of TAK1 [8][22][120]. TAK1 is a common signaling component
between the NFκB and MAPK pathways. This corroborates the data showing that the
majority of the inflammatory cytokines enhanced in HIES are targets of the terminal
transcription factors of these two pathways (NFκB and AP-1) [114-116]. Due to the
deregulation of both of these pathways in patients with HIES and mice lacking STAT3
in the hematopoietic system [66][67][84][89][121](Table1), we hypothesized that
STAT3 might act to negatively regulates both pathways through a common signaling
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component, however confirming this was out of the scope of the current project. We
chose to focus on whether STAT3 was negatively regulating these pathways via a
transcriptional mechanism or an alternative method.
Our data indicated an importance for the SH2 domain in regulating
osteoclastogenesis through the use of an antagonistic inhibitor for this domain (Fig.
16). Due to difficulties in differentiating the RAW cells, in addition to technical issues
infecting primary murine macrophages, we were unable to verify the involvement of
the other domains using the STAT3 HIES mutants. However, we can establish a
tenuous indirect importance of the DNA-binding and SH2 domains due to the presence
of osteoclastogenesis deregulation in patients carrying mutations in these domains
[89][98].
With regards to the enhanced inflammatory gene expression seen in both
human patients and hematopoietic STAT3-deficient mice, we have clearly indicated a
function for the DNA-binding domain, SH2 domain, and TAD in this regulation. In all
three cases, we saw increased mRNA expression of Il6, Cxcl10, Tnf compared to WT
STAT3. Even in non-hematopoietic tissues, such as MEFs, we have shown that
STAT3 expression significantly reduced the mRNA expression of Il6, Cxcl10, Il12 (Fig.
18). However, in non-hematopoietic cells, the HIES mutants may not be acting as they
do in the macrophages because we see a significant reduction in expression of these
genes after LPS stimulation (Fig. 19) which is in stark contrast to our data comparing
GFP-empty vector transduced cells with WT STAT3 transduced cells (Fig. 18). This
may indicate that MEFs are not a good system for our analysis or, more likely that the
mechanism we hypothesize that is leading to increase inflammatory gene expression,
is not active in non-hematopoietic cells.
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Next we wanted to further examine the developing relationship between STAT3
and NFκB. To this point, we had only shown indirectly that loss of STAT3 function, by
mutation or exogenous inhibition of the DNA-binding domain, SH2 domain, or TAD
leads to increased gene expression of inflammatory mediators, which are NFκB and
AP-1 targets, and enhanced osteoclastogenesis, a process that is NFκB-dependent.
Therefore, we intended to examine whether the loss of STAT3 function led to
increased NFκB activation. Preliminary results examining phosphorylation of the
inhibitor of NFκB, IκBα, showed enhanced phosphorylation as well as enhanced
degradation (data not shown), which follows this phosphorylation [122]. We examined
the phosphorylation of JNK1, which is part of the MAPK pathway downstream of TAK1
activation and serves to activate the AP-1 family of transcription factors [113][114].
Cells expressing the HIES mutants began activating JNK1 as early as 5 minutes poststimulation (Fig. 20), which was significant because cells expressing WT STAT3 did
not exhibit JNK phosphorylation until 30 minutes post-LPS stimulation. This suggests
that MAPK signaling, induced by TLR4 activation of macrophages, is negatively
regulated by STAT3 and most likely deregulated in patients with HIES.
In this study, we have shown that STAT3 negatively regulates NFκB and
MAPK-mediated inflammatory gene expression in both macrophages and nonhematopoietic fibroblasts. In addition, we found that STAT3 inhibits the expression of
genes specific for osteoclastogenesis, a process that is NFκB dependent. We have
shown that the SH2 domain is required for this regulation and that the DNA binding
domain and the TAD are also involved in regulating the inflammatory gene expression.
From our analysis of the point mutations identified in patients with HIES, we have
confirmed previous reports regarding the activation capabilities of STAT3 when
mutations occur in the DNA-binding and SH2 domains and we were the first to show
	
  

84	
  

that the V713L mutation doesn’t completely block STAT3 phosphorylation or
transcriptional function. We demonstrated that the R382W, V637M, and V713L
mutants elicit dominant negative activity either through reduction of luciferase reporter
transcription or endogenous Socs3 expression. Data regarding the V637M mutant
disagreed, raising several questions regarding how this mutation leads to the
inflammatory and bone phenotypes observed in HIES. We have developed several
alternative hypotheses, which will allow us to pursue answers to these questions in
future studies.
In one model, the V637M mutation could reduce the amount of global STAT3
signals within the cell, which would be significant, as it would show what even a slight
loss in STAT3 signaling could lead to. However in light of data in mice heterozygous
for Stat3 [52], this seems unlikely. Another possibility came out of the evidence that
this mutant STAT3 protein cannot be phosphorylated. Several groups have identified
roles for unphosphorylated STAT3 (U-STAT3), which could offer alternative
explanations for the observations obtained in this study regarding the V637M mutation.
U-STAT3 has been shown to bind NFκB after IL-6 stimulation and lead to its activation
by displacement of IκBα [68]. Another group identified a role for the Drosophila
melanogaster STAT protein in maintaining heterochromatin stability [61] while a role
was also identified for STAT4 and STAT6 in epigenetic modifications [64]. These
observations could indicate that it is possible unphosphorylated STAT3 could regulate
heterochromatin in such a way that it remains closed to the transcription of NFκBinhibiting proteins. However, we have to be careful to not overanalyze our data as this
mutation could also function only to block binding and activation at the receptor but not
to activated STAT3 monomers, something that has not been investigated.
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Our data indicates a role for STAT3 in regulating NFκB and MAPK signaling via
its intrinsic transcriptional activity, and highlights the necessity for two fully functional
STAT3 alleles. However there are gaps that need to be filled prior to drawing any
further, definitive conclusions. To extend this work, we intend to determine what
STAT3’s transcriptional target is and which protein in the NFκB pathway it is acting to
repress. Secondly, we would like to determine the mechanism by which the V637M
mutation is affecting STAT3’s regulation of NFκB signaling. Since STAT3 monomers
carrying this mutation cannot be phosphorylated, presumably they cannot bind
phosphorylated STAT3 monomers. This indicates that only WT STAT3 monomers
would be involved in the signaling. Thus the defect seen in our system as well as
patients with this mutation remains to be determined, but could either be due to the
reduction in activatable STAT3 or an unknown mechanism for unphosphorylated
STAT3. Finally, we intend to confirm whether the V713L mutation destabilizes STAT3.
Does the instability affect binding at the receptor, the promoter, or somewhere in
between? Could it be due to some other reason, such as a conformational changes
shielding the tyrosine residue from the receptor associated JAKs or phosphorylation of
the serine residue located with this domain?
Regardless of the several questions which this study raises, we have extended
knowledge of the mechanism leading to enhanced inflammation and osteoporosis in
patients with HIES. We have also established STAT3 as a negative regulator of NFκBand MAPK- induced inflammatory gene expression and MAPK activation.
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Figure 21. Schematic diagram of our working model for the interplay
between STAT3 and NFκB/MAPK. Diagram representing WT STAT3
negatively regulating NFκB/MAPK leading to repressed inflammatory and
osteoclast-specific gene expression. NFκB and MAPK signaling gets
activated which leads to expression of STAT3-activating signals. These
lead to STAT3 aiding in the transcription of a gene which goes on to
repress proteins upstream of TAK1 thereby inhibiting further NFκB and
MAPK activation. Dotted arrows represent a diminished signal.
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Figure 22. Diagram representing our working model with regards
to how the HIES mutants affect the regulation seen in Figure 21.
The HIES mutants interfere with STAT3’s transcription of “gene
x” thus enhancing NFκB-mediated gene transcription. The
R382W mutant inhibits the ability to bind DNA, whereas the
V637M mutant acts through an unknown mechanism, and the
V713L mutation possibly destabilizes STAT3’s dimerization or
interaction at the receptor. Bolded arrows represent an enhanced
signal.
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